适合挽救治疗的复发性激素敏感前列腺癌患者接受68Ga-PSMA-11 PET/CT后的无事件生存
该研究纳入176例根治性治疗后生化复发、适合挽救治疗的激素敏感且未使用激素的前列腺癌患者,评估68Ga-PSMA-11 PET/CT后的无事件生存(EFS)。中位随访35.4个月,1年、2年、3年EFS分别为78.8%、65.2%、52.2%。PSA>0.5 ng/mL、PSA倍增时间≤6个月和PSMA-PET阳性与更高事件率相关,PSMA-PET阴性者EFS更长。
要点
- PSA>0.5 ng/mL和PSA倍增时间≤6个月是多因素模型中显著的事件预测因素(p<0.001)。
- PSMA-PET阴性患者无事件生存期显著更长。
- PSMA-PET后治疗管理改变与未改变的患者之间事件率无显著差异。
核心结论
- 低PSA和长PSA倍增时间是更长无事件生存的显著预测因素。
- PSMA-PET阴性患者事件发生率更低,因为阴性扫描时更长EFS的概率显著更高。
研究设计与样本
- 前瞻性研究纳入连续、激素敏感、未使用激素的复发性前列腺癌患者,均适合挽救治疗且PSMA-PET后至少随访24个月。
- 共分析176例患者,中位PSA 0.62 ng/mL(IQR:0.43-1.00),中位随访35.4个月(IQR:26.5-40.3)。
- 主要终点为无事件生存(EFS),定义为PSMA-PET至事件日期或末次随访的时间;采用Kaplan-Meier法和Cox比例风险回归分析。
- 事件定义为死亡、影像学进展或治疗后PSA复发。
主要发现
- EFS在1年时为78.8%,2年时为65.2%,3年时为52.2%。
- 发生事件的患者中位PSA为0.81 ng/mL(IQR:0.53-1.28),高于无事件患者的0.51 ng/mL(IQR:0.36-0.80)(p<0.001)。
- 发生事件的患者中位PSA倍增时间为5.4个月(IQR:3.7-11.6),低于无事件患者的12.7个月(IQR:6.6-24.3)(p<0.001)。
- Kaplan-Meier曲线显示PSA>0.5 ng/mL、PSA倍增时间≤6个月和PSMA-PET阳性结果与更高事件率相关(p<0.01)。
- PSMA-PET后接受治疗管理改变的患者与未接受治疗改变的患者之间事件率无显著差异。
关键数值与推荐
- 多因素模型中PSA>0.5 ng/mL和PSA倍增时间≤6个月为统计学显著的事件预测因素(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIM: Prostate-specific-membrane-antigen/positron emission tomography (PSMA-PET) detects with high accuracy disease-recurrence, leading to changes in the management of biochemically-recurrent (BCR) prostate cancer (PCa). However, data regarding the oncological outcomes of patients who performed PSMA-PET are needed. The aim of this study was to evaluate the incidence of clinically relevant events during follow-up in patients who performed PSMA-PET for BCR after radical treatment. MATERIALS AND METHODS: This analysis included consecutive, hormone-sensitive, hormone-free, recurrent PCa patients (HSPC) enrolled through a prospective study. All patients were eligible for salvage therapy, having at least 24 months of follow-up after PSMA-PET. The primary endpoint was the Event-Free Survival (EFS), defined as the time between the PSMA-PET and the date of event/last follow-up. The Kaplan-Meier method was used to estimate the EFS curves. EFS was also investigated by Cox proportional hazards regression. Events were defined as death, radiological progression, or PSA recurrence after therapy. RESULTS: One-hundred and seventy-six (n = 176) patients were analyzed (median PSA 0.62 [IQR: 0.43-1.00] ng/mL; median follow-up of 35.4 [IQR: 26.5-40.3] months). The EFS was 78.8% at 1 year, 65.2% (2 years), and 52.2% (3 years). Patients experiencing events during study follow-up had a significantly higher median PSA (0.81 [IQR: 0.53-1.28] vs 0.51 [IQR: 0.36-0.80] ng/mL) and a lower PSA doubling time (PSAdt) (5.4 [IQR: 3.7-11.6] vs 12.7 [IQR: 6.6-24.3] months) (p < 0.001) compared to event-free patients. The Kaplan-Meier curves showed that PSA > 0.5 ng/mL, PSAdt ≤ 6 months, and a positive PSMA-PET result were associated with a higher event rate (p < 0.01). No significant differences of event rates were observed in patients who received changes in therapy management after PSMA-PET vs. patients who did not receive therapy changes. Finally, PSA > 0.5 ng/mL and PSAdt ≤ 6 months were statistically significant event-predictors in multivariate model (p < 0.001). CONCLUSION: Low PSA and long PSAdt were significant predictors of longer EFS. A lower incidence of events was observed in patients having negative PSMA-PET, since longer EFS was significantly more probable in case of a negative scan.
引用
- Ceci F, Rovera G, Iorio GC, et al. Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy. Eur J Nucl Med Mol Imaging. 2022. PMID: 35217883. doi:10.1007/s00259-022-05741-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。